olfactory receptor family 51 subfamily AB member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51AB1P profile across patient tissues and cancer cell-line models. OR51AB1P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OR51AB1P is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, OR51AB1P RNA expression shows 5,427 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCS, UCEC, and LIHC as cancer lineages where OR51AB1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51AB1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51AB1P survival associations across molecular data types. OR51AB1P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51AB1P RNA expression–survival associations across cancer types. High OR51AB1P expression shows unfavorable associations in KICH, UVM, HNSC, READ and LUSC, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for OR51AB1P RNA expression.
This table summarizes OR51AB1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for OR51AB1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51AB1P shows lower tumor expression in UCEC, BRCA, LUAD and LUSC and higher tumor expression in THCA and KIRP. The UCEC box plot shows higher OR51AB1P RNA expression in normal versus tumor tissue (log2 FC = −0.093, t-test p = .004).
This table shows molecular features associated with OR51AB1P in patient tissues and cancer cell lines. In patient samples, OR51AB1P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
